Insider Buying Activity Uncovered - 5 Stocks On The Rise

This is a must read. If you cannot see this email properly, please click [here]( --------------------------------------------------------------- Sponsor Message [Game-Changing Cancer Tech Nears FDA Completion]( [Explore Investment Opportunities in This Market Disruptor]( --------------------------------------------------------------- April 3, 2024 Editorial Insights Insider trading occurs when company executives or major shareholders trade stocks based on non-public information. Monitoring these trades provides insight into insiders' expectations for the company's future. For instance, significant purchases before public announcements may indicate anticipated positive news and a potential share price increase. Note: "Insider Buying" is legal stock purchasing by company directors or officers, distinct from illegal insider trading based on non-public information. It's not a crime when based on public information. Insiders, having unique insights, often buy shares when they believe the stock is undervalued. This report lists stocks recently identified with substantial insider buying. --------------------------------------------------------------- Sponsor Message [Revolutionary Device Redefines Cancer Detection]( the breakthrough device that could transform the lives of the estimated 68 million Americans affected by skin cancer. Achieving unprecedented accuracy, this device identifies cancer's molecular signature in just 1.5 seconds. This innovation marks a rapid advance in the battle against cancer. See how investors are unlocking 10% in bonus shares for a limited time. [Learn More Now - Before Anticipated FDA Approval in 2024]( --------------------------------------------------------------- [Citi Trends, Inc.]( Ticker: [CTRN]( Recent Price: $27.02 Average Analyst Price Target: $28.33 (4.86%) Market Cap: $230.87M Role Transaction Description No. of Shares Amount Date >10% Owner Informative Buy Non Open Market Buy 18,000 $487,760 2 Days Ago Recent Analyst Action: Michael Baker, analyst at D.A. Davidson, reiterates coverage on [Citi Trends, Inc. (CTRN)]( in the Consumer Cyclical sector with a Buy rating (2 weeks ago). Here are 3rd party ratings for [CTRN](: - TipRanks.com: Buy - Yahoo! Finance: Neutral Short-Term Outlook - Barchart.com: buy - Zacks.com: n/a, n/a [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Dividend Expert Reveals His Biggest Income Secrets... Free of Charge]( Marc Lichtenfeld –Author of the best-selling book Get Rich With Dividends – is giving away his Ultimate Dividend Package… [Free of charge!]( [Click Here to Get His #1 Dividend Stock… The Safest 9% Dividend in the World… Top Three “Extreme Dividend” Stocks, And Much, Much More]( --------------------------------------------------------------- [Ameresco, Inc.]( Ticker: [AMRC]( Recent Price: $23.86 Average Analyst Price Target: $34.00 (42.50%) Market Cap: $1.25B Role Transaction Description No. of Shares Amount Date Director Informative Buy Options Exercised and fully kept 10,000 $67,000 2 Days Ago Recent Analyst Action: Pavel Molchanov, analyst at Raymond James, reiterates coverage on [Ameresco, Inc. (AMRC)]( in the Industrials sector with a Buy rating and a price target of $35 (9 hours ago). Here are 3rd party ratings for [AMRC](: - TipRanks.com: Buy - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: sell - Zacks.com: Strong Sell, Top 24% (60 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [I Couldn't Air my Biggest A.I. Prediction]( built the indicator that Wall Street uses to find winning stocks. Now he's issuing a new prediction about the A.I. market. [Learn more here.]( --------------------------------------------------------------- [Greenwich LifeSciences, Inc.]( Ticker: [GLSI]( Recent Price: $17.49 Average Analyst Price Target: $36.00 (105.83%) Market Cap: $224.72M Role Transaction Description No. of Shares Amount Date CEO and CFO,Director, >10% Owner Informative Buy Non Open Market Buy 3,272 $57,240 2 Days Ago Recent Analyst Action: Yi Chen, analyst at H.C. Wainwright, reiterates coverage on [Greenwich LifeSciences, Inc. (GLSI)]( in the Healthcare sector with a Buy rating and a price target of $36 (1 month ago). Here are 3rd party ratings for [GLSI](: - TipRanks.com: Buy - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Hold, Top 29% (74 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- [Inspire Medical Systems, Inc.]( Ticker: [INSP]( Recent Price: $205.06 Average Analyst Price Target: $239.00 (16.55%) Market Cap: $6.07B Role Transaction Description No. of Shares Amount Date Director Informative Buy Non Open Market Buy 255 $52,368 2 Days Ago Recent Analyst Action: Travis Steed, analyst at Bank of America Securities, reiterates coverage on [Inspire Medical Systems, Inc. (INSP)]( in the Healthcare sector with a Buy rating and a price target of $265 (1 week ago). Here are 3rd party ratings for [INSP](: - TipRanks.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: buy - Zacks.com: Buy, Bottom 42% (146 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Imminent FDA Decision Could End Obesity in America...]( [...and spark a 224,000% sales surge for one tiny micro-cap stock.]( The Wall Street Journal Reports: The "King Kong" of drugs is coming. Barron's Reports: "it's game changing." [Get the name of the stock here ]( --------------------------------------------------------------- [CalciMedica, Inc.]( Ticker: [CALC]( Recent Price: $4.04 Average Analyst Price Target: $18.25 (351.73%) Market Cap: $41.44M Role Transaction Description No. of Shares Amount Date CBO,Director, >10% Owner Informative Buy Non Open Market Buy 4,000 $15,600 2 Days Ago Recent Analyst Action: Joseph Pantginis, analyst at H.C. Wainwright, reiterates coverage on [CalciMedica, Inc. (CALC)]( in the Healthcare sector with a Buy rating and a price target of $20 (2 days ago). Here are 3rd party ratings for [CALC](: - TipRanks.com: Buy - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Weak buy - Zacks.com: Buy, Top 29% (74 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Richest investors clearly worried about something big]( Dalio, John Paulson, and many others all recommend you own gold right now. But did you know there's another huge investor (worth more than all the world's billionaires COMBINED) buying gold by the ton? That's why the best move to make right now could be this little-known gold investment (which you can get started with for just $5.) [Click for full story.]( --------------------------------------------------------------- And there you have it. To Your Financial Freedom, The Editor MarketInsidersPress.com Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. Content marked as "Ad," "Special" or "Sponsor" may be third-party advertisements where the advertiser is paying per click, per lead, or per sale and are not endorsed or warranted by our staff or company. SPMG, AITickers.com and its principles do not own any of the stocks mentioned in this email or in the article that this email links to. Please see the disclaimer on the advertiser's website for additional information, including their relationship with any mentioned security. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged not to use this newsletter as the basis for any investment decision. This newsletter may contain information regarding investment ideas and third-party ratings regarding specific securities. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. SPMG, AITickers.com nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from SPMG or AITickers.com to buy or sell any security. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. By opening this email or clicking any links contained, you are reconfirming your opt-in status. You can unsubscribe at any time by clicking the link below in the footer. This is part of your free subscription to MarketInsidersPress.com MarketInsidersPress.com 1519 Mecklenburg Hwy Unit 4 | Mt. Mourne | NC | 28123 | United States | 877 411 9808 MarketInsidersPress.com part of Sandpiper Marketing Group, LLC | 1519 Mecklenburg Hwy | Unit 4 | Mount Mourne | NC | 28123 | United States | 877-411-9808 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software